ArticleCost effectiveness and resource allocation : C/E2023

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration.

Zi-Rong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.